FP09.04 Impact of Brain Metastasis Status on Adverse Events (AEs) Requiring Dose Reduction Among Patients Receiving Lorlatinib

Abstract

Anaplastic lymphoma kinase (ALK)-rearranged (ALK+) and ROS1-rearranged (ROS1+) non-small cell lung cancers (NSCLC) are associated with a propensity towards central nervous system (CNS) dissemination. Lorlatinib is a third-generation tyrosine kinase inhibitor (TKI) that is approved for treatment of metastatic ALK+ NSCLC based on robust intracranial and extracranial activity. Although not approved for ROS1+ NSCLC, lorlatinib is widely used for treatment of this disease based on its promising systemic activity in the post-crizotinib setting, including among patients with brain metastasis.